Last reviewed · How we verify
Safety and Efficacy of L19TNF in Patients With Isocitrate Dehydrogenase (IDH) Wildtype WHO Grade III / IV Glioma at First Relapse (GLIOMOON)
Open label, non-randomized, mono-center Phase I/II study in subjects with IDH-wildtype WHO grade III / IV glioma at first relapse.
Details
| Lead sponsor | Philogen S.p.A. |
|---|---|
| Phase | PHASE1, PHASE2 |
| Status | COMPLETED |
| Enrolment | 20 |
| Start date | Fri May 31 2019 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Tue Jun 27 2023 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Glioma of Brain
Interventions
- L19TNF
Countries
Switzerland